Moderna's cancer vaccine powers on with AACR data

17 April 2023
moderna-logo-large

US biotech Moderna (Nasdaq: MRNA) continues to add to the optimism over mRNA-4157 (V940), its investigational cancer vaccine being developed alongside Merck & Co (NYSE: MRK).

The mRNA specialist has announced the first presentation of detailed results from the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial evaluating the vaccine alongside Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV).

In the overall intention-to-treat population, adjuvant treatment with mRNA-4157 (V940) in combination with Keytruda demonstrated a statistically-significant and clinically-meaningful improvement in recurrence-free survival (RFS), and reduced the risk of recurrence or death by 44% compared with Keytruda alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology